Literature DB >> 28649511

Why does Leigh syndrome respond to immunotherapy?

Josef Finsterer1, Sinda Zarrouk-Mahjoub2.   

Abstract

Entities:  

Keywords:  Immunosuppression; Leigh syndrome; Mitochondrial DNA; Plasmapheresis; Respiratory chain

Year:  2016        PMID: 28649511      PMCID: PMC5470935          DOI: 10.1016/j.ymgmr.2016.07.008

Source DB:  PubMed          Journal:  Mol Genet Metab Rep        ISSN: 2214-4269


× No keyword cloud information.
Letter to the Editor With interest we read the article by Chuquilin et al. about a 20yo female with Leigh syndrome due to the m.9176T > C mutation in the ATP6 gene who responded favourably to plasmapheresis and immunoglobulins [1]. We have the following comments and concerns. The main ambiguity of this report is the diagnosis. Except for the current case, Leigh syndrome has not been reported to respond to immunosuppressive treatment. Thus, the diagnosis of Leigh syndrome needs to be challenged. Which of the four variants in the ATP6, POLG1, DARS2, and LRPPRC respectively was the causative mutation? Was any of these mutations also detected in any of the parents or grandparents? Was there consanguinity between mother and father? Did the parents or other first degree relatives undergo neurologic work-up for mitochondrial disorder? Particularly the mother requires intensive work-up since she had a history of migraine, a frequent phenotypic manifestation of mitochondrial disorders [2]. Did the patient undergo muscle biopsy and a biochemical investigation? Were any deficiencies in the activity of the respiratory chain complexes detected? Did magnetic resonance spectroscopy (MRS) confirm elevated lactate in the cerebrum, particularly the basal ganglia [3]? Was glycogen storage disease 3A genetically confirmed in one of the half-brothers? Did the patient or her relatives ever experience a stroke-like episode, seizures, migraine, or a psychotic episode? Second, POLG1 mutations may not only cause CPEO, Alpers-Huttenlocher, and SANDO, but also mitochondrial depletion syndrome, encephalomyopathy, mitochondrial epilepsy, mitochondrial neuropathy, a MNGIE-like phenotype, MELAS/SANDO overlap syndrome, POLG-related levodopa-related parkinsonism, and a number of complex non-syndromic mitochondrial disorders [4], [5]. Third, we should be informed if plasmapheresis and immunoglobulins also had a beneficial effect on the cerebral lesions? Was follow-up MRI and MRS normal? Overall, this interesting case merits confirmation of the genetic diagnosis and a plausible explanation why immunosuppression had such a beneficial effect.

Conflict of interest

There are no conflicts of interest.

Funding

No funding was received.
  4 in total

Review 1.  Leigh and Leigh-like syndrome in children and adults.

Authors:  Josef Finsterer
Journal:  Pediatr Neurol       Date:  2008-10       Impact factor: 3.372

2.  Proton MR Spectroscopy in Patients with Leigh Syndrome.

Authors:  E Jurkiewicz; S Chełstowska; I Pakuła-Kościesza; K Malczyk; K Nowak; M Bekiesińska-Figatowska; J Sykut-Cegielska; D Piekutowska-Abramczuk; E Pronicka
Journal:  Neuroradiol J       Date:  2011-06-24

3.  Progressive myoclonic epilepsy as an adult-onset manifestation of Leigh syndrome due to m.14487T>C.

Authors:  B Dermaut; S Seneca; L Dom; K Smets; L Ceulemans; J Smet; B De Paepe; S Tousseyn; S Weckhuysen; M Gewillig; P Pals; P Parizel; J L De Bleecker; P Boon; L De Meirleir; P De Jonghe; R Van Coster; W Van Paesschen; P Santens
Journal:  J Neurol Neurosurg Psychiatry       Date:  2010-01       Impact factor: 10.154

4.  Response to immunotherapy in a patient with adult onset Leigh syndrome and T9176C mtDNA mutation.

Authors:  Miguel Chuquilin; Raghav Govindarajan; Dawn Peck; Esperanza Font-Montgomery
Journal:  Mol Genet Metab Rep       Date:  2016-07-01
  4 in total
  1 in total

1.  Defined neuronal populations drive fatal phenotype in a mouse model of Leigh syndrome.

Authors:  Irene Bolea; Alejandro Gella; Elisenda Sanz; Patricia Prada-Dacasa; Fabien Menardy; Angela M Bard; Pablo Machuca-Márquez; Abel Eraso-Pichot; Guillem Mòdol-Caballero; Xavier Navarro; Franck Kalume; Albert Quintana
Journal:  Elife       Date:  2019-08-12       Impact factor: 8.140

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.